newsfilter
← Latest News
GlobeNewswire·

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

The U.S. Food and Drug Administration ("FDA") accepted Celcuity's New Drug Application ("NDA") and granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") goal date of July 17, 2026, for gedatolisib in